Daiichi sets up vaccine R&D unit in Japan

Daiichi Sankyo has established a new Tokyo-based vaccine research unit at its existing Kasai R&D Center in Japan. The move follows the April announcement that Daiichi had set up another research unit inside the National Institute of Biomedical Innovation in Osaka, where the Japanese developer says it's already conducting exploratory vaccine research and searching for new adjuvants.

Researchers at the Tokyo unit will be hunting for new vaccines for infectious diseases, according to Daiichi's release. "Now, with two vaccine research units and partnerships with organizations inside and outside of the group, Daiichi Sankyo is poised to fully realize its dedication to producing new vaccines through continuing research efforts and to supplying safe and effective existing vaccines to the healthcare professionals and other persons in Japan who are waiting for them," the pharma company said in a statement.

- see this release from Daiichi

Related Article:
Daiichi shuffles R&D programs in global restructuring

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.